NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Thanks. Yes, I think sending them back for a confirmatory trial would not be practical nor would it work, given what we know. And it is not consistent with their other approvals of less promising treatments. As a rare disease as well and given all the further confirmatory data, it would make no sense. Not to say that regulators always do that which makes sense, but I think they would necessarily come to their senses when they’d see what many of us see.